Novel therapies for myelofibrosis

References

• Mesa RA, Kiladjian JJ, Verstovsek S, et al. Comparison of placebo and best available therapy for the treatment of myelofibrosis in the phase 3 COMFORT studies. Haematologica 2014;99:292–298.
   PubMed Web of Science ®Google Scholar
• James C, Ugo V, Le Couedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005;434:1144–1148.
   PubMed Web of Science ®Google Scholar
• Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005;352:1779–1790.
   PubMed Web of Science ®Google Scholar
• Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005;365:1054–1061.
   PubMed Web of Science ®Google Scholar
• Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005;7:387–397.
   PubMed Web of Science ®Google Scholar
• Verstovsek S, Kantarjian H, Mesa RA, et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Eng J Med 2010;363:1117–1127.
   PubMed Web of Science ®Google Scholar
• Verstovsek S, Mesa RA, Gotlib J, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med 2012;366:799–807.
   PubMed Web of Science ®Google Scholar
• Harrison C, Kiladjian JJ, Al-Ali HK, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med 2012;366:787–798.
   PubMed Web of Science ®Google Scholar
• Cervantes F, Vannucchi AM, Kiladjian JJ, et al. Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. Blood 2013;122:4047–4053.
   PubMed Web of Science ®Google Scholar
• Verstovsek S, Mesa RA, Gotlib J, et al. Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I. Haematologica 2013;98:1865–1871.
   PubMed Web of Science ®Google Scholar
• Verstovsek S, Mesa RA, Gotlib J, et al. Three-year efficacy, overall survival, and safety of ruxolitinib therapy in patients with myelofibrosis from the COMFORT-I study. Haematologica 2015;100:479–488.
   PubMed Web of Science ®Google Scholar
• Rampal R, Al-Shahrour F, Abdel-Wahab O, et al. Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis. Blood 2014;123:e123–e133.
   PubMed Web of Science ®Google Scholar
• Vainchenker W, Constantinescu SN. JAK/STAT signaling in hematological malignancies. Oncogene 2013;32:2601–2613.
   PubMed Web of Science ®Google Scholar
• Bhagwat N, Koppikar P, Keller M, et al. Improved targeting of JAK2 leads to increased therapeutic efficacy in myeloproliferative neoplasms. Blood 2014;123:2075–2083.
   PubMed Web of Science ®Google Scholar
• Klampfl T, Gisslinger H, Harutyunyan AS, et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med 2013;369:2379–2390.
   PubMed Web of Science ®Google Scholar
• Passamonti F, Caramazza D, Maffioli M. JAK inhibitor in CALR-mutant myelofibrosis. N Engl J Med 2014;370:1168–1169.
   PubMed Web of Science ®Google Scholar
• Nangalia J, Massie CE, Baxter EJ, et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med 2013;369:2391–2405.
   PubMed Web of Science ®Google Scholar
• Rumi E, Pietra D, Pascutto C, et al. Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis. Blood 2014;124:1062–1069.
   PubMed Web of Science ®Google Scholar
• Tefferi A, Lasho TL, Tischer A, et al. The prognostic advantage of calreticulin mutations in myelofibrosis might be confined to type 1 or type 1-like CALR variants. Blood 2014;124:2465–2466.
   PubMed Web of Science ®Google Scholar
• Beer PA, Campbell PJ, Scott LM, et al. MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort. Blood 2008;112:141–149.
   PubMed Web of Science ®Google Scholar
• Vainchenker W, Delhommeau F, Constantinescu SN, et al. New mutations and pathogenesis of myeloproliferative neoplasms. Blood 2011;118:1723–1735.
   PubMed Web of Science ®Google Scholar
• Pikman Y, Lee BH, Mercher T, et al. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med 2006;3:e270.
   PubMed Web of Science ®Google Scholar
• Pardanani A, Guglielmelli P, Lasho TL, et al. Primary myelofibrosis with or without mutant MPL: comparison of survival and clinical features involving 603 patients. Leukemia 2011;25:1834–1839.
   PubMed Web of Science ®Google Scholar
• Heine A, Held SA, Daecke SN, et al. The JAK-inhibitor ruxolitinib impairs dendritic cell function in vitro and in vivo. Blood 2013;122: 1192–1202.
   PubMed Web of Science ®Google Scholar
• Wathes R, Moule S, Milojkovic D. Progressive multifocal leukoencephalopathy associated with ruxolitinib. N Engl J Med 2013;369:197–198.
   PubMed Web of Science ®Google Scholar
• Goldberg RA, Reichel E, Oshry LJ. Bilateral toxoplasmosis retinitis associated with ruxolitinib. N Engl J Med 2013;369:681–683.
   PubMed Web of Science ®Google Scholar
• Hopman RK, Lawrence SJ, Oh ST. Disseminated tuberculosis associated with ruxolitinib. Leukemia 2014;28:1750–1751.
   PubMed Web of Science ®Google Scholar
• Colomba C, Rubino R, Siracusa L, et al. Disseminated tuberculosis in a patient treated with a JAK2 selective inhibitor: a case report. BMC Res Notes 2012;5:552.
   PubMedGoogle Scholar
• Wysham NG, Sullivan DR, Allada G. An opportunistic infection associated with ruxolitinib, a novel janus kinase 1,2 inhibitor. Chest 2013;143:1478–1479.
   PubMed Web of Science ®Google Scholar
• Guglielmelli P, Biamonte F, Rotunno G, et al. Impact of mutational status on outcomes in myelofibrosis patients treated with ruxolitinib in the COMFORT-II study. Blood 2014;123:2157–2160.
   PubMed Web of Science ®Google Scholar
• Verstovsek S, Kantarjian HM, Estrov Z, et al. Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls. Blood 2012;120:1202–1209.
   PubMed Web of Science ®Google Scholar
• Passamonti F, Maffioli M, Cervantes F, et al. Impact of ruxolitinib on the natural history of primary myelofibrosis: a comparison of the DIPSS and the COMFORT-2 cohorts. Blood 2014;123:1833–1835.
   PubMed Web of Science ®Google Scholar
• Barosi G, Gale RP. Reply to Passamonti et al.: ruxolitinib and survival improvement in patients with myelofibrosis. Leukemia 2015;29:740.
   PubMed Web of Science ®Google Scholar
• Barosi G, Zhang MJ, Peter Gale R. Does ruxolitinib improve survival of persons with MPN-associated myelofibrosis? Should it? Leukemia 2014;28:2267–2270.
   PubMed Web of Science ®Google Scholar
• Thiele J, Bueso-Ramos CE, Sun W, et al. Effects of five-years of ruxolitinib therapy on bone marrow morphology in patients with myelofibrosis and comparison with best available therapy. Blood 2013;122:4055.
   Google Scholar
• Talpaz M, Paquette R, Afrin L, et al. Interim analysis of safety and efficacy of ruxolitinib in patients with myelofibrosis and low platelet counts. J Hematol Oncol 2013;6:81.
   PubMed Web of Science ®Google Scholar
• Pardanani A, Laborde RR, Lasho TL, et al. Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis. Leukemia 2013;27:1322–1327.
   PubMed Web of Science ®Google Scholar
• Pardanani A, Gotlib J, Gupta V, et al. Update on the long-term efficacy and safety of momelotinib, a JAK1 and JAK2 inhibitor, for the treatment of myelofibrosis. Blood 2013;122:108.
   Web of Science ®Google Scholar
• Verstovsek S, Odenike O, Scott B, et al. Phase I dose-escalation trial of SB1518, a novel JAK2/FLT3 inhibitor, in acute and chronic myeloid diseases, including primary or post-essential thrombocythemia/polycythemia vera myelofibrosis. ASH Annual Meeting Abstracts. Blood 2009;114: Abstract 3905.
   PubMed Web of Science ®Google Scholar
• Komrokji RS, Wadleigh M, Seymour JF, et al. Results of a phase 2 study of pacritinib (SB1518), a novel oral JAK2 inhibitor, in patients with primary, post-polycythemia vera, and post-essential thrombocythemia myelofibrosis. ASH Annual Meeting Abstracts. Blood 2011;118: Abstract 282.
   Google Scholar
• Verstovsek S, Liang S, Komrokji R, et al. Safety overview of phase I–II studies of pacritinib, a nonmyelosuppressive JAK2/FLT3 inhibitor, in patients with hematological malignancies. Haematologica 2013;98(s1):111 (abstract p 278).
   Google Scholar
• Verstovsek S, Dean JP, Cernohous P, et al. Pacritinib, a dual JAK2/FLT3 inhibitor: an integrated efficacy and safety analysis of phase II trial data in patients with primary and secondary myelofibrosis (MF) and platelet counts ≤ 100,000/μl. Blood 2013;122:395.
   Web of Science ®Google Scholar
• Verstovsek S, Mesa RA, Rhoades SK, et al. Phase I study of the JAK2 V617F inhibitor, LY2784544, in patients with myelofibrosis (MF), polycythemia vera (PV), and essential thrombocythemia (ET). ASH Annual Meeting Abstracts 2011;118:2814.
   Google Scholar
• Mesa RA, Salama ME, Giles JLK, et al. Phase I study of LY2784544, a JAK2 selective inhibitor, in patients with myelofibrosis (MF), polycythemia vera (PV), and essential thrombocythemia (ET). Blood 2013;122:665.
   Web of Science ®Google Scholar
• Pardanani A, Roberts AW, Seymour JF, et al. BMS-911543, A selective JAK2 inhibitor: a multicenter phase 1/2a study in myelofibrosis. Blood 2013;122:664.
   Web of Science ®Google Scholar
• Mascarenhas JO, Talpaz M, Gupta V, et al. Primary analysis results from an open-label phase II study of INCB039110, a selective JAK1 inhibitor, in patients with myelofibrosis. ASH Annual Meeting Abstracts. Blood 2014;124: Abstract 714.
   Google Scholar
• Verstovsek S, Talpaz M, Ritchie EK, et al. A phase 1/2, open-label, dose-escalation, multi-center study to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of orally administered NS-018 in patients with primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (post-PV MF). ASH Annual Meeting Abstracts. Blood 2014;124: Abstract 1839.
   Google Scholar
• Harrison CN, Cortes JE, Cervantes F, et al. Results of a randomized, double-blind, placebo-controlled phase III study (JAKARTA) of the JAK2-selective inhibitor fedratinib (SAR302503) in patients with myelofibrosis (MF). Blood 2013;122:393.
   Web of Science ®Google Scholar
• Shah NP, Olszynski P, Sokol L, et al. A phase I study of XL019, a selective JAK2 inhibitor, in patients with primary myelofibrosis, post-polycythemia vera, or post-essential thrombocythemia myelofibrosis. ASH Annual Meeting Abstracts. Blood 2008;112: Abstract 98.
   Google Scholar
• Tefferi A, Pardanani A. Serious adverse events during ruxolitinib treatment discontinuation in patients with myelofibrosis. Mayo Clin Proc 2011;86:1188–1191.
   PubMed Web of Science ®Google Scholar
• Koppikar P, Bhagwat N, Kilpivaara O, et al. Heterodimeric JAK-STAT activation as a mechanism of persistence to JAK2 inhibitor therapy. Nature 2012;489:155–159.
   PubMed Web of Science ®Google Scholar
• Garber K. JAK2 inhibitors: not the next imatinib but researchers see other possibilities. J Natl Cancer Inst 2009;101:980–982.
   PubMed Web of Science ®Google Scholar
• Jhaveri K, Modi S. HSP90 inhibitors for cancer therapy and overcoming drug resistance. Adv Pharmacol 2012;65:471–517.
   PubMedGoogle Scholar
• Marubayashi S, Koppikar P, Taldone T, et al. HSP90 is a therapeutic target in JAK2-dependent myeloproliferative neoplasms in mice and humans. J Clin Invest 2010;120:3578–3593.
   PubMed Web of Science ®Google Scholar
• Bareng J, Jilani I, Gorre M, et al. A potential role for HSP90 inhibitors in the treatment of JAK2 mutant-positive diseases as demonstrated using quantitative flow cytometry. Leuk Lymphoma 2007;48:2189–2195.
   PubMed Web of Science ®Google Scholar
• Weigert O, Lane AA, Bird L, et al. Genetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibition. J Exp Med 2012;209:259–273.
   PubMed Web of Science ®Google Scholar
• Fiskus W, Verstovsek S, Manshouri T, et al. Heat shock protein 90 inhibitor is synergistic with JAK2 inhibitor and overcomes resistance to JAK2-TKI in human myeloproliferative neoplasm cells. Clin Cancer Res 2011;17:7347–7358.
   PubMed Web of Science ®Google Scholar
• Proia DA, Foley KP, Korbut T, et al. Multifaceted intervention by the Hsp90 inhibitor ganetespib (STA-9090) in cancer cells with activated JAK/STAT signaling. PLoS One 2011;6:e18552.
   PubMed Web of Science ®Google Scholar
• Vannucchi AM, Lasho TL, Guglielmelli P, et al. Mutations and prognosis in primary myelofibrosis. Leukemia 2013;27:1861–1869.
   PubMed Web of Science ®Google Scholar
• Teofili L, Martini M, Cenci T, et al. Epigenetic alteration of SOCS family members is a possible pathogenetic mechanism in JAK2 wild type myeloproliferative diseases. Int J Cancer 2008;123:1586–1592.
   PubMed Web of Science ®Google Scholar
• Wang JC, Chen C, Dumlao T, et al. Enhanced histone deacetylase enzyme activity in primary myelofibrosis. Leuk Lymphoma 2008;49:2321–2327.
   PubMed Web of Science ®Google Scholar
• Mascarenhas J, Roper N, Chaurasia P, et al. Epigenetic abnormalities in myeloproliferative neoplasms: a target for novel therapeutic strategies. Clin Epigenetics 2011;2:197–212.
   PubMed Web of Science ®Google Scholar
• Dawson MA, Bannister AJ, Gottgens B, et al. JAK2 phosphorylates histone H3Y41 and excludes HP1alpha from chromatin. Nature 2009;461:819–822.
   PubMed Web of Science ®Google Scholar
• Mascarenhas J, Lu M, Li T, et al. A phase I study of panobinostat (LBH589) in patients with primary myelofibrosis (PMF) and post-polycythaemia vera/essential thrombocythaemia myelofibrosis (post-PV/ET MF). Br J Haematol 2013;161:68–75.
   PubMed Web of Science ®Google Scholar
• DeAngelo DJ, Mesa RA, Fiskus W, et al. Phase II trial of panobinostat, an oral pan-deacetylase inhibitor in patients with primary myelofibrosis, post-essential thrombocythaemia, and post-polycythaemia vera myelofibrosis. Br J Haematol 2013;162:326–335.
   PubMed Web of Science ®Google Scholar
• Baffert F, Evrot E, Ebel N, et al. Improved efficacy upon combined JAK1/2 and pan-deacetylase inhibition using ruxolitinib (INC424) and panobinostat (LBH589) in preclinical mouse models of JAK2V617F-driven disease. ASH Annual Meeting Abstracts. Blood 2011;118: Abstract 798.
   Google Scholar
• Kiladjian J-J, Heidel FH, Vannucchi AM, et al. Efficacy, safety, and confirmation of the recommended phase 2 dose of ruxolitinib plus panobinostat in patients with intermediate or high-risk myelofibrosis, ASH Annual Meeting Abstracts. Blood 2010;124:Abstract 711.
   Google Scholar
• Rambaldi A, Dellacasa CM, Finazzi G, et al. A pilot study of the Histone-Deacetylase inhibitor Givinostat in patients with JAK2V617F positive chronic myeloproliferative neoplasms. Br J Haematol 2010;150:446–455.
   PubMed Web of Science ®Google Scholar
• Quintas-Cardama A, Kantarjian H, Estrov Z, et al. Therapy with the histone deacetylase inhibitor pracinostat for patients with myelofibrosis. Leuk Res 2012;36:1124–1127.
   PubMed Web of Science ®Google Scholar
• Andersen CL, Mortensen NB, Klausen TW, et al. A phase II study of vorinostat (MK-0683) in patients with primary myelofibrosis and post-polycythemia vera myelofibrosis. Haematologica 2014;99:e5–7.
   PubMed Web of Science ®Google Scholar
• Quintas-Cardama A, Tong W, Kantarjian H, et al. A phase II study of 5-azacitidine for patients with primary and post-essential thrombocythemia/polycythemia vera myelofibrosis. Leukemia 2008;22:965–970.
   PubMed Web of Science ®Google Scholar
• Mesa RA, Verstovsek S, Rivera C, et al. 5-Azacitidine has limited therapeutic activity in myelofibrosis. Leukemia 2009;23:180–182.
   PubMed Web of Science ®Google Scholar
• Thepot S, Itzykson R, Seegers V, et al. Treatment of progression of Philadelphia-negative myeloproliferative neoplasms to myelodysplastic syndrome or acute myeloid leukemia by azacitidine: a report on 54 cases on the behalf of the Groupe Francophone des Myelodysplasies (GFM). Blood 2010;116:3735–3742.
   PubMed Web of Science ®Google Scholar
• Odenike OM, Godwin JE, Van Besien K, et al. Phase II trial of low dose, subcutaneous decitabine in myelofibrosis. ASH Annual Meeting Abstracts. Blood 2008;112: Abstract 2809.
   Google Scholar
• Danilov AV, Relias V, Feeney DM, et al. Decitabine is an effective treatment of idiopathic myelofibrosis. Br J Haematol 2009;145:131–132.
   PubMed Web of Science ®Google Scholar
• Liu Y, Tabarroki A, Billings S, et al. Successful use of very low dose subcutaneous decitabine to treat high-risk myelofibrosis with Sweet syndrome that was refractory to 5-azacitidine. Leuk Lymphoma 2014;55:447–449.
   PubMed Web of Science ®Google Scholar
• Tabarroki A, Saunthararajah Y, Visconte V, et al. Ruxolitinib in combination with DNA methyltransferase inhibitors; clinical responses in symptomatic myelofibrosis patients with cytopenias and elevated blasts counts. Leuk Lymphoma 2015;56:497–499.
   PubMed Web of Science ®Google Scholar
• Guglielmelli P, Barosi G, Rambaldi A, et al. Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase study in patients with myelofibrosis. Blood 2011;118:2069–2076.
   PubMed Web of Science ®Google Scholar
• Vannucchi AM, Bogani C, Bartalucci N, et al. The mTOR Inhibitor, RAD001, inhibits the growth of cells from patients with myeloproliferative neoplasms. ASH Annual Meeting Abstracts. Blood 2009;114: Abstract 2914.
   Google Scholar
• Vannucchi AM, Bogani C, Bartalucci N, et al. Inhibitors of PI3K/Akt and/or mTOR inhibit the growth of cells of myeloproliferative neoplasms and synergize with JAK2 inhibitor and interferon. ASH Annual Meeting Abstracts. Blood 2011;118: Abstract 3835.
   Google Scholar
• Bogani C, Bartalucci N, Martinelli S, et al. mTOR inhibitors alone and in combination with JAK2 inhibitors effectively inhibit cells of myeloproliferative neoplasms. PLoS One 2013;8:e54826.
   PubMed Web of Science ®Google Scholar
• Durrant S, Koren-Michowitz M, Lavie D, et al. HARMONY: An open-label, multicenter, 2-arm, dose-finding, phase 1b study of the combination of ruxolitinib and buparlisib (BKM120) in patients with myelofibrosis (MF). ASH Annual Meeting Abstracts. Blood 2014;124(21):710.
   PubMedGoogle Scholar
• Khan I, Huang Z, Wen Q, et al. AKT is a therapeutic target in myeloproliferative neoplasms. Leukemia 2013;27:1882–1890.
   PubMed Web of Science ®Google Scholar
• Tibes R, Mesa RA. Targeting hedgehog signaling in myelofibrosis and other hematologic malignancies. J Hematol Oncol 2014;7:18.
   PubMed Web of Science ®Google Scholar
• Jamieson C, Cortes JE, Oehler V, et al. Phase 1 dose-escalation study of PF-04449913, an oral hedgehog (Hh) inhibitor, in patients with select hematologic malignancies. ASH Annual Meeting Abstracts. Blood 2011;118: Abstract 424.
   Google Scholar
• Sasaki KG, Gotlib JR, Mesa RA, et al. A phase 2 study of IPI-926, an oral hedgehog inhibitor, in patients with myelofibrosis. J Clin Oncol 2014;32:5s(suppl; abstr 7111).
   PubMed Web of Science ®Google Scholar
• Bhagwat N, Keller MD, Rampal RK, et al. Improved efficacy of combination of JAK2 and hedgehog inhibitors in myelofibrosis. Blood 2013;122:666.
   PubMed Web of Science ®Google Scholar
• Gupta V, Koschmieder S, Harrison CN, et al. Phase 1b dose-escalation study of sonidegib (LDE225) in combination with ruxolitinib (INC424) in patients with myelofibrosis. ASH Annual Meeting Abstracts. Blood 2014;124:712.
   Web of Science ®Google Scholar
• Papadantonakis N, Matsuura S, Ravid K. Megakaryocyte pathology and bone marrow fibrosis: the lysyl oxidase connection. Blood 2012;120:1774–1781.
   PubMed Web of Science ®Google Scholar
• Dillingh MR, van den Blink B, Moerland M, et al. Recombinant human serum amyloid P in healthy volunteers and patients with pulmonary fibrosis. Pulm Pharmacol Ther 2013;26:672–676.
   PubMed Web of Science ®Google Scholar
• Verstovsek S, Mesa RA, Foltz LM, et al. Phase 2 trial of PRM-151, an anti-fibrotic agent, in patients with myelofibrosis: stage 1 results. ASH Annual Meeting Abstracts. Blood 2014;124:713.
   Google Scholar
• Goldenson B, Malinge S, Stein BL, et al. Aurora A kinase is a novel therapeutic target in the myeloproliferative neoplasms. Blood 2013;122:109.
   PubMed Web of Science ®Google Scholar
• Stubig T, Alchalby H, Ditschkowski M, et al. JAK inhibition with ruxolitinib as pretreatment for allogeneic stem cell transplantation in primary or post-ET/PV myelofibrosis. Leukemia 2014;28:1736–1738.
   PubMed Web of Science ®Google Scholar
• Ruxolitinib before allogeneic hematopoietic stem cell transplantation (HSCT) in patients with myelofibrosis: a preliminary descriptive report of the JAK ALLO study, a phase II trial sponsored by Goelams-FIM in collaboration with the SFGMTC, 2013.
   Google Scholar
• Tefferi A, LaPlant BR, Begna K, et al. Imetelstat, a telomerase inhibitor, therapy for myelofibrosis: a pilot study. ASH Annual Meeting Abstracts. Blood 2014;124:634.
   Google Scholar
• Cervantes F, Alvarez-Larran A, Domingo A, et al. Efficacy and tolerability of danazol as a treatment for the anaemia of myelofibrosis with myeloid metaplasia: long-term results in 30 patients. Br J Haematol 2005;129:771–775.
   PubMed Web of Science ®Google Scholar
• Shimoda K, Shide K, Kamezaki K, et al. The effect of anabolic steroids on anemia in myelofibrosis with myeloid metaplasia: retrospective analysis of 39 patients in Japan. Int J Hematol 2007;85:338–343.
   PubMed Web of Science ®Google Scholar
• Gowin KL, Dueck AC, Mascarenhas JO, et al. Interim analysis of a phase II pilot trial of ruxolitinib combined with danazol for patients with primary myelofibrosis (MF), post essential thrombocythemia-myelofibrosis (post ET), and post polycythemia vera myelofibrosis (PV MF) suffering from anemia. ASH Annual Meeting Abstracts. Blood 2014;124:3206.
   Google Scholar
• Cervantes F, Alvarez-Larran A, Hernandez-Boluda JC, et al. Erythropoietin treatment of the anaemia of myelofibrosis with myeloid metaplasia: results in 20 patients and review of the literature. Br J Haematol 2004;127:399–403.
   PubMed Web of Science ®Google Scholar
• Cervantes F, Alvarez-Larran A, Hernandez-Boluda JC, et al. Darbepoetin-alpha for the anaemia of myelofibrosis with myeloid metaplasia. Br J Haematol 2006;134:184–186.
   PubMed Web of Science ®Google Scholar
• McMullin MF, Harrison CN, Niederwieser D, et al. The use of erythropoietic-stimulating agents (ESAs) with ruxolitinib in patients with primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF), and post-essential thrombocythemia myelofibrosis (PET-MF). ASH Annual Meeting Abstracts. Blood 2012;120: Abstract 2838.
   Google Scholar
• Mesa RA, Yao X, Cripe LD, et al. Lenalidomide and prednisone for myelofibrosis: Eastern Cooperative Oncology Group (ECOG) phase 2 trial E4903. Blood 2010;116:4436–4438.
   PubMed Web of Science ®Google Scholar
• Jabbour E, Thomas D, Kantarjian H, et al. Comparison of thalidomide and lenalidomide as therapy for myelofibrosis. Blood 2011;118:899–902.
   PubMed Web of Science ®Google Scholar
• Naval D, Cortes JE, Jabbour E, et al. Ruxolitinib and lenalidomide as a combination therapy for patients with myelofibrosis. ASH Annual Meeting Abstracts. Blood 2014;124:1831.
   Google Scholar
• Passamonti F, Barbui T, Barosi G, et al. Phase 3 study of pomalidomide in myeloproliferative neoplasm (MPN)-associated myelofibrosis with RBC-transfusion-dependence. Blood 2013; 122:394.
   PubMed Web of Science ®Google Scholar
• Stegelmann F, Griesshammer M, Reiter A, et al. A multicenter phase-Ib/II study of ruxolitinib/pomalidomide combination therapy in patients with primary and secondary myelofibrosis: safety data from the Mpnsg-0212 trial (NCT01644110). ASH Annual Meeting Abstracts: Blood 2014;124:3161.
   Google Scholar
• Silver RT, Vandris K, Goldman JJ. Recombinant interferon-alpha may retard progression of early primary myelofibrosis: a preliminary report. Blood 2011;117:6669–6672.
   PubMed Web of Science ®Google Scholar
• Hasselbalch HC. The role of cytokines in the initiation and progression of myelofibrosis. Cytokine Growth Fact Rev 2013;24: 133–145.
   PubMed Web of Science ®Google Scholar